GM-CSF Gene therapy using adenoviral vector in hamster pancreatic cancer

Takahiro Ogawa, Masahiro Kusumoto, Kazuhiro Mizumoto, Norihiro Sato, Eishi Nagai, Akashi Ikubo, Yasuaki Aoki, Masao Tanaka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study was to examine the antitumor effect of irradiated granulocyte macrophage-colony-stimulating factor (GM-CSF)-gene-transduced hamster pancreatic cancer cells and its relationship to the amount of GM-CSF produced by transduced tumor cells. Hamster pancreatic adenocarcinuma cells, HPD1NR, which spontaneously secrete 15.0 ± 0.4pg/106 cells per 24h of GM-CSF, and HPD2NR cells, which do not secrete GM-CSF, were used. When these cells were infected with recombinant adenovirus harboring the GM-CSF gene, HPD1NR and HPD2NR secreted 624.2 ± 9.9 and 157.8 ± 5.7pg/106 cells per 24h. respectively. Vaccination with irradiated GM-CSF-secreting HPD2NR completely protected syngeneic hamsters challenged with live parental cells. On the other hand, vaccination with irradiated HPD1NR protected 60% of hamsters from tumor development after challenge with parental cells. None of the tumor-free hamsters initially vaccinated with irradiated GM-CSF-producing HPD2NR cells developed tumor upon repeated challenge with parental cells during the entire observation period. Irradiated GM-CSF-gene-transduced hamster pancreatic cells are promising as a novel adjuvant cancer therapy after surgery for primary and metastatic pancreatic cancer. The results indicate the necessity for a therapeutic strategy for cancer based on the cytokine status of tumors.

Original languageEnglish
Pages (from-to)306-311
Number of pages6
JournalJournal of Hepato-Biliary-Pancreatic Surgery
Volume7
Issue number3
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Pancreatic Neoplasms
Cricetinae
Genetic Therapy
Neoplasms
Vaccination
Genes
Adenoviridae
Observation
Cytokines

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology

Cite this

GM-CSF Gene therapy using adenoviral vector in hamster pancreatic cancer. / Ogawa, Takahiro; Kusumoto, Masahiro; Mizumoto, Kazuhiro; Sato, Norihiro; Nagai, Eishi; Ikubo, Akashi; Aoki, Yasuaki; Tanaka, Masao.

In: Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 7, No. 3, 01.01.2000, p. 306-311.

Research output: Contribution to journalArticle

Ogawa, T, Kusumoto, M, Mizumoto, K, Sato, N, Nagai, E, Ikubo, A, Aoki, Y & Tanaka, M 2000, 'GM-CSF Gene therapy using adenoviral vector in hamster pancreatic cancer', Journal of Hepato-Biliary-Pancreatic Surgery, vol. 7, no. 3, pp. 306-311. https://doi.org/10.1007/s005340070053
Ogawa, Takahiro ; Kusumoto, Masahiro ; Mizumoto, Kazuhiro ; Sato, Norihiro ; Nagai, Eishi ; Ikubo, Akashi ; Aoki, Yasuaki ; Tanaka, Masao. / GM-CSF Gene therapy using adenoviral vector in hamster pancreatic cancer. In: Journal of Hepato-Biliary-Pancreatic Surgery. 2000 ; Vol. 7, No. 3. pp. 306-311.
@article{ae6a2bb1d6214b21b01098514ecb2e4c,
title = "GM-CSF Gene therapy using adenoviral vector in hamster pancreatic cancer",
abstract = "The aim of this study was to examine the antitumor effect of irradiated granulocyte macrophage-colony-stimulating factor (GM-CSF)-gene-transduced hamster pancreatic cancer cells and its relationship to the amount of GM-CSF produced by transduced tumor cells. Hamster pancreatic adenocarcinuma cells, HPD1NR, which spontaneously secrete 15.0 ± 0.4pg/106 cells per 24h of GM-CSF, and HPD2NR cells, which do not secrete GM-CSF, were used. When these cells were infected with recombinant adenovirus harboring the GM-CSF gene, HPD1NR and HPD2NR secreted 624.2 ± 9.9 and 157.8 ± 5.7pg/106 cells per 24h. respectively. Vaccination with irradiated GM-CSF-secreting HPD2NR completely protected syngeneic hamsters challenged with live parental cells. On the other hand, vaccination with irradiated HPD1NR protected 60{\%} of hamsters from tumor development after challenge with parental cells. None of the tumor-free hamsters initially vaccinated with irradiated GM-CSF-producing HPD2NR cells developed tumor upon repeated challenge with parental cells during the entire observation period. Irradiated GM-CSF-gene-transduced hamster pancreatic cells are promising as a novel adjuvant cancer therapy after surgery for primary and metastatic pancreatic cancer. The results indicate the necessity for a therapeutic strategy for cancer based on the cytokine status of tumors.",
author = "Takahiro Ogawa and Masahiro Kusumoto and Kazuhiro Mizumoto and Norihiro Sato and Eishi Nagai and Akashi Ikubo and Yasuaki Aoki and Masao Tanaka",
year = "2000",
month = "1",
day = "1",
doi = "10.1007/s005340070053",
language = "English",
volume = "7",
pages = "306--311",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - GM-CSF Gene therapy using adenoviral vector in hamster pancreatic cancer

AU - Ogawa, Takahiro

AU - Kusumoto, Masahiro

AU - Mizumoto, Kazuhiro

AU - Sato, Norihiro

AU - Nagai, Eishi

AU - Ikubo, Akashi

AU - Aoki, Yasuaki

AU - Tanaka, Masao

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The aim of this study was to examine the antitumor effect of irradiated granulocyte macrophage-colony-stimulating factor (GM-CSF)-gene-transduced hamster pancreatic cancer cells and its relationship to the amount of GM-CSF produced by transduced tumor cells. Hamster pancreatic adenocarcinuma cells, HPD1NR, which spontaneously secrete 15.0 ± 0.4pg/106 cells per 24h of GM-CSF, and HPD2NR cells, which do not secrete GM-CSF, were used. When these cells were infected with recombinant adenovirus harboring the GM-CSF gene, HPD1NR and HPD2NR secreted 624.2 ± 9.9 and 157.8 ± 5.7pg/106 cells per 24h. respectively. Vaccination with irradiated GM-CSF-secreting HPD2NR completely protected syngeneic hamsters challenged with live parental cells. On the other hand, vaccination with irradiated HPD1NR protected 60% of hamsters from tumor development after challenge with parental cells. None of the tumor-free hamsters initially vaccinated with irradiated GM-CSF-producing HPD2NR cells developed tumor upon repeated challenge with parental cells during the entire observation period. Irradiated GM-CSF-gene-transduced hamster pancreatic cells are promising as a novel adjuvant cancer therapy after surgery for primary and metastatic pancreatic cancer. The results indicate the necessity for a therapeutic strategy for cancer based on the cytokine status of tumors.

AB - The aim of this study was to examine the antitumor effect of irradiated granulocyte macrophage-colony-stimulating factor (GM-CSF)-gene-transduced hamster pancreatic cancer cells and its relationship to the amount of GM-CSF produced by transduced tumor cells. Hamster pancreatic adenocarcinuma cells, HPD1NR, which spontaneously secrete 15.0 ± 0.4pg/106 cells per 24h of GM-CSF, and HPD2NR cells, which do not secrete GM-CSF, were used. When these cells were infected with recombinant adenovirus harboring the GM-CSF gene, HPD1NR and HPD2NR secreted 624.2 ± 9.9 and 157.8 ± 5.7pg/106 cells per 24h. respectively. Vaccination with irradiated GM-CSF-secreting HPD2NR completely protected syngeneic hamsters challenged with live parental cells. On the other hand, vaccination with irradiated HPD1NR protected 60% of hamsters from tumor development after challenge with parental cells. None of the tumor-free hamsters initially vaccinated with irradiated GM-CSF-producing HPD2NR cells developed tumor upon repeated challenge with parental cells during the entire observation period. Irradiated GM-CSF-gene-transduced hamster pancreatic cells are promising as a novel adjuvant cancer therapy after surgery for primary and metastatic pancreatic cancer. The results indicate the necessity for a therapeutic strategy for cancer based on the cytokine status of tumors.

UR - http://www.scopus.com/inward/record.url?scp=0033642883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033642883&partnerID=8YFLogxK

U2 - 10.1007/s005340070053

DO - 10.1007/s005340070053

M3 - Article

C2 - 10982631

AN - SCOPUS:0033642883

VL - 7

SP - 306

EP - 311

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 3

ER -